甲状腺肿瘤精准诊治研究进展

doi:10.3969/j.issn.1009-976X.2021.04.002

岭南现代临床外科 ›› 2021, Vol. 21 ›› Issue (04): 383-386.DOI: 10.3969/j.issn.1009-976X.2021.04.002

甲状腺肿瘤精准诊治研究进展

张乘, 罗定远, 黎洪浩

中山大学孙逸仙纪念医院甲状腺外科,广州 510120

通讯作者: *黎洪浩,Emial: lihh8@163.com
作者简介:黎洪浩,医学博士,主任医师,硕士生导师, 中山大学孙逸仙纪念医院甲状腺外科主任。中国研究型医院学会甲状腺疾病专业委员会常务委员,围手术期学组副组长、对外交流学组常委、神经监测学组委员、微创及分子诊断学组委员;中国医师协会外科医师分会甲状腺外科学组委员;中国抗癌协会肿瘤微创治疗专业委员会甲状腺分会常务委员;中国抗癌协会甲状腺癌专业委员会委员;中国医疗保健国际交流促进会甲状腺疾病防治分会委员、颈清扫学组副组长;广东省医学教育协会甲状腺专业委员会主任委员;广东省医师协会甲状腺专业医师分会副主任委员、神经监测专业组组长;广东省抗癌协会甲状腺癌专业委员会副主任委员;广东省医学会外科学分会甲状腺与甲状旁腺学组副组长;广东省临床医学学会甲状腺专业委员会副主任委员。

Progress in precise diagnosis and treatment of thyroid tumors

ZHANG Cheng, LUO Ding-yuan, LI Hong-hao

Department of Thyroid, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

Online:2021-08-20 Published:2021-12-09
Contact: LI Hong-hao, lihh8@163.com

摘要/Abstract

摘要： 甲状腺肿瘤的精准诊治近年来取得了很大进展,涉及到甲状腺肿瘤细胞和分子层面的诸多精准诊断技术以及基于精准诊断而产生的各种新兴治疗手段。本文将试从上述方面对甲状腺肿瘤精准诊治的进展进行综述。

关键词: 精准医疗, 分化型甲状腺癌, 细针穿刺, 分子医学

Abstract: The precise diagnosis and treatment of thyroid tumors has made great progress recent years, involving many precise diagnostic techniques on cellular and molecular levels of thyroid tumors,andvarious emerging treatment methods based on precise diagnosis. This article will try to review the progress of precise diagnosis and treatment of thyroid tumors from the above aspects.

Key words: precision medicine, DTC, FNA, molecular medicine

中图分类号:

R736.1

张乘, 罗定远, 黎洪浩. 甲状腺肿瘤精准诊治研究进展[J]. 岭南现代临床外科, 2021, 21(04): 383-386.

ZHANG Cheng, LUO Ding-yuan, LI Hong-hao. Progress in precise diagnosis and treatment of thyroid tumors[J]. Lingnan Modern Clinics In Surgery, 2021, 21(04): 383-386.

参考文献

[1] 张浩, 孙威, 田文. 分化型甲状腺癌基础研究热点及未来方向[J]. 中国实用外科杂志, 2021, 41(01):76-79.
[2] 田文, 郗洪庆. 分化型甲状腺癌外科诊疗进展及展望[J]. 中国实用外科杂志,2020, 40(01):78-82.
[3] 曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床, 2019, 46(03):145-149.
[4] Yoo JY, Stang MT.Current Guidelines for Postoperative Treatment and Follow-Up of Well-Differentiated Thyroid Cancer[J]. Surg Oncol Clin N Am, 2016, 25(1):41-59.
[5] Grani G, Lamartina L, Durante C, et al.Follicular thyroid cancer and Hurthle cell carcinoma: challenges in diagnosis, treatment, and clinical management[J]. Lancet Diabetes Endocrinol, 2018, 6(6): 500-514.
[6] Yip L, Sosa JA.Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment[J]. JAMA Surg, 2016, 151(7): 663-670.
[7] Thorneycroft IH.Thyroid cancer[J]. Clin Obstet Gynecol, 2002, 45(3): 879-883.
[8] Perri F, Giordano A, Pisconti S, et al.Thyroid cancer management: from a suspicious nodule to targeted therapy[J]. Anticancer Drugs, 2018, 29(6): 483-490.
[9] Lechner MG, Praw SS, Angell TE.Treatment of Differentiated Thyroid Carcinomas[J]. Surg Pathol Clin, 2019, 12(4): 931-942.
[10] Xing M, Haugen BR, Schlumberger M.Progress in molecular-based management of differentiated thyroid cancer[J]. Lancet, 2013, 381(9871): 1058-1069.
[11] 罗定远, 欧阳能太. 甲状腺癌分子诊断的现状与展望[J]. 临床外科杂志, 2020, 28(3):285-288.
[12] Haugen BR, Alexander EK, Bible KC, et al.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1): 1-133.
[13] Tumino D, Grani G, Di Stefano M, et al.Nodular Thyroid Disease in the Era of Precision Medicine[J]. Front Endocrinol(Lausanne), 2019, 10: 907.
[14] 中华人民共和国国家卫生健康委员会. 甲状腺癌诊疗规范(2018年版)[J]. 中华普通外科学文献(电子版), 2019, 13(1):1-15.
[15] Lebastchi AH, Callender GG.Thyroid cancer[J]. Curr Probl Cancer, 2014, 38(2): 48-74.
[16] Raue F, Frank-Raue K.Thyroid Cancer: Risk-Stratified Management and Individualized Therapy[J]. Clin Cancer Res, 2016, 22(20): 5012-5021.
[17] Choi JS, Kim J, Kwak JY, et al.Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT[J]. AJR Am J Roentgenol, 2009, 193(3): 871-878.
[18] Cibas ES, Ali SZ.The 2017 Bethesda System for Reporting Thyroid Cytopathology[J]. Thyroid, 2017, 27(11): 1341-1346.
[19] Cheung CC, Carydis B, Ezzat S, et al.Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer[J]. J Clin Endocrinol Metab, 2001, 86(5): 2187-2190.
[20] Kimura ET, Nikiforova MN, Zhu Z, et al.High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma[J]. Cancer Res, 2003, 63(7): 1454-1457.
[21] Sciacchitano S, Paliotta DS, Nardi F, et al.PCR amplification and analysis of ras oncogenes from thyroid cytologic smears[J]. Diagn Mol Pathol, 1994, 3(2): 114-121.
[22] Ferrari SM, Fallahi P, Ruffilli I, et al.Molecular testing in the diagnosis of differentiated thyroid carcinomas[J]. Gland Surg, 2018, 7(Suppl 1): S19-S29.
[23] Gambelunghe G. Stefanetti E, Avenia N, et al.Percutaneous Ultrasound-Guided Laser Ablation of Benign Thyroid Nodules: Results of 10-Year Follow-Up in 171 Patients[J]. J Endocr Soc, 2021, 5(7): b81.
[24] Ji L, Wu Q, Gu J, et al.Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients[J]. Cancer Imaging, 2019, 19(1): 16.
[25] Mauri G, Hegedus L, Bandula S, et al.European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions[J]. Eur Thyroid J, 2021, 10(3): 185-197.
[26] Schlumberger M, Tahara M, Wirth LJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7): 621-630.
[27] Brose MS, Nutting CM, Jarzab B, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940): 319-328.
[28] Wells SJ, Robinson BG, Gagel RF, et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(2): 134-141.
[29] Schlumberger M, Elisei R, Muller S, et al.Overall survival analysis of EXAM, a phase Ⅲ trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma[J]. Ann Oncol, 2017, 28(11): 2813-2819.
[30] Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials[J]. Lancet Oncol, 2020, 21(4): 531-540.
[31] Doebele RC, Drilon A, Paz-Ares L, et al.Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020, 21(2): 271-282.
[32] Bradford D, Larkins E, Mushti SL, et al.FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions[J]. Clin Cancer Res, 2021, 27(8): 2130-2135.
[33] Subbiah V, Gainor JF, Rahal R, et al.Precision Targeted Therapy with BLU-667 for RET-Driven Cancers[J]. Cancer Discov, 2018, 8(7): 836-849.
[34] Li D, Chi Y, Chen X, et al.Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial[J]. Clin Cancer Res, 2021,27(3):3567-3575.
[35] Shen G, Zheng F, Ren D, et al.Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018, 11(1): 120.
[36] 罗定远, 廖健伟. 甲状腺癌基因检测与临床应用广东专家共识(2020版)[J]. 中华普通外科学文献(电子版), 2020, 14(3):161-168.

甲状腺肿瘤精准诊治研究进展

Progress in precise diagnosis and treatment of thyroid tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

[1]	周毅林启谋黄文俊李勇袁琳. 左旋甲状腺素抑制治疗对分化型甲状腺癌女性患者骨密度的影响分析[J]. 岭南现代临床外科, 2017, 17(04): 428-431.
[2]	胡志刚王捷. 精准医疗时代肝细胞肝癌诊疗策略[J]. 岭南现代临床外科, 2016, 16(01): 1-6.